Abrocitinib scores wins for AD

Expert Name
Dr Ricardo Rojo Cella

The Phase 3 JADE REGIMEN study (NCT03627767) was a 52-week study investigated abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200mg. The JADE REGIMEN results build on the positive results from the JADE MONO-1 and 2…

A screenshot of a cell phone Description automatically generated

1-Minute Summary: COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey

Expert Name
Andrea Matucci, MD

In this descriptive study the association between severe asthma, biological therapy, and SARS-CoV-2 infection was investigated [1]. A higher risk for viral infections was described previously for asthmatic patients [2,3]. Because SARS-CoV-2 has demonstrated a predisposition to infect the upper and the lower respiratory tract, it may create a higher clinical issue for this patient group [4]. However, it should…

1-Minute Summary: Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation

Expert Name
Haiyu Hong

The concept of united airway diseases (UAD) includes allergic rhinitis (AR), chronic rhinosinusitis (CRS), and asthma, all of which share common immune-pathogenic mechanisms [1-4]. Moreover, a systemic link between upper and lower airways exists by shared molecular and inflammatory mechanisms, including overproduction of type-2 cytokines in AR, CRS, and asthma [5,6], not limited to the target organs. There is a…

1-Minute Summary: Functional interaction between sensory neurons and mast cells in the early stage of house dust mite-induced type 2 inflammation and itch: a novel therapeutic target of allergic disease

Expert Name
Miranda Sin-Man Tsang and Chun Kwok Wong

The interaction between the nervous system and immune cells has been reported in fungal-infected skin inflammation and psoriasis, but not in atopic dermatitis (AD) [1-3]. Antihistamines are not always effective in treating pruritus in chronic skin inflammation [4]. A recent study by Serhan et al. unraveled how house dust mite allergens can trigger peripheral nociceptive sensory neurons and how these…

Good response and pruritus reduction in AD with novel selective JAK1 inhibitor

Expert Name
Dr Melinda Gooderham

The JADE Mono-2 study in adolescent and adult patients with atopic dermatitis (AD) investigated the efficacy and safety of abrocitinib. The results demonstrated significant advantages in clinical signs and symptoms over placebo [1,2]. The randomised, controlled, double-blind, phase 3 trial included 391 patients aged ≥12 years with moderate-to-severe AD from 115 centres worldwide and was presented by Dr Melinda Gooderham…

Baricitinib beneficial in head and neck AD

New data from a pooled analysis of phase 3 trials demonstrated substantial efficacy of JAK-inhibition with baricitinib for head and neck lesions in atopic dermatitis (AD) [1]. The oral JAK1/JAK2 inhibitor baricitinib has already proven its efficacy versus placebo in treating moderate-to-severe AD in the identical, double-blind, randomised, controlled, phase 3 BREEZE-AD1 and BREEZE-AD2 trials. Patients with AD often experience…

IL-4/IL-13 blocker dupilumab effective in children with severe AD

Expert Name
Prof. Amy S. Paller

The IL-4/IL-13 blocker dupilumab leads to rapid symptom control and itch reduction in children with severe atopic dermatitis (AD), as was demonstrated in the phase 3 LIBERTY AD PEDS study [1]. Previous trials have already shown that dupilumab is effective in adults and adolescents ≥12 years with moderate-to-severe AD inadequately controlled with topical prescription therapies. However, there is also an…

IL-13 blocker tralokinumab effective in AD

Expert Name
Prof. Eric Simpson

IL-13 plays a key role in pathogenesis of atopic dermatitis (AD). The phase 3 ECZTRA trials demonstrated the remarkable efficacy of the IL-13 blocker tralokinumab in adult patients with moderate-to-severe AD [1]. AD is a chronic inflammatory skin disease. Tralokinumab is a fully human monoclonal antibody designed specifically to neutralise IL-13, a key driver of the underlying inflammation in AD,…

1-Minute Summary: Dupilumab Improves Clinical Outcomes in Patients with Asthma and Perennial Allergic Rhinitis

Expert Name
Dr William W. Busse

Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis [published online ahead of print, 2020 May 28]. Ann Allergy Asthma Immunol. 2020;S1081-1206(20)30389-6. In this post-hoc analysis of the phase 3 LIBERTY ASTHMA QUEST trial, the effect of dupilumab on comorbid perennial allergic rhinitis (PAR) was investigated. PAR is often associated with sensitisation to indoor allergens…

1-Minute Summary: Development and Preliminary Validation of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO)

Expert Name
Dr Saied Ghadersohi

Ghadersohi S, Price CPE, Jensen SE, et al. Development and Preliminary Validation of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO). J Allergy Clin Immunol Pract. 2020;8(7):2341-2350.e1. Chronic rhinosinusitis (CRS) is an inflammatory disease of the nasal airways and paranasal sinuses with a high disease burden [1,2]. Patient-reported outcome (PRO) instruments are measures of disease severity and symptom burden in…